Pharma giant Sanofi charged with manslaughter

Sanofi Aventis France has been charged by prosecutors in France with manslaughter over birth defects related to a drug prescribed around the world to treat epilepsy -- charges it denies and is challenging.

The charges relate to the drug sodium valproate, or Depakine as it is better known. Studies say the drug has caused disabilities in up to 30,000 children whose mothers took the medicine while pregnant.

The long-running case has also seen the pharmaceutical company charged with aggravated deceipt and causing involuntary harm.

Depakine has been on the market since 1967, and the company insists it had warned authorities of the drug's risks in the 1980s.

Separately, Sanofi has said that it is in "advanced discussions" with GSK and the European Union to supply up to 300 million doses of a COVID-19 vaccine. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology. The doses would be manufactured in European countries including France, Belgium, Germany and Italy.

Image: Sanofi Corporate

    Share Story:

Recent Stories

Financial institutions were early adopters of cyber security and insurance. Are they still on top of the game?
Managing huge amounts of sensitive data online makes financial institutions a prime target for hackers. As such, the sector was an early cohort for insurers in creating cyber cover. Since then, the market has evolved almost beyond recognition. It continues to challenge itself to this day, complying with rigorous regulatory demands and implementing avant-garde enhancements to keep abreast of the ever-changing risks.

Manufacturing: An industry at risk amid great technological change
Of the many sectors of business, manufacturing companies are among the most at risk from cyber threats. How has the sector evolved to make it so vulnerable and what does the task of managing cyber exposure in a manufacturing company look like? CIR’s latest podcast with Tokio Marine HCC sought to answer all these questions and more. Published April 2021